Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2019

Open Access 01-12-2019 | Prostate Cancer | Research

SNW1 is a prognostic biomarker in prostate cancer

Authors: Doris Höflmayer, Carla Willich, Claudia Hube-Magg, Ronald Simon, Dagmar Lang, Emily Neubauer, Frank Jacobsen, Andrea Hinsch, Andreas M. Luebke, Marie Christina Tsourlakis, Hartwig Huland, Markus Graefen, Alexander Haese, Hans Heinzer, Sarah Minner, Franziska Büscheck, Guido Sauter, Thorsten Schlomm, Stefan Steurer, Till S. Clauditz, Eike Burandt, Waldemar Wilczak, Christian Bernreuther

Published in: Diagnostic Pathology | Issue 1/2019

Login to get access

Abstract

Background

SNW1 is a nuclear receptor co-activator involved in splicing and transcription control, including androgen receptor signaling. Overexpression of SNW1 has been linked to adverse prognosis in different cancer types, but studies on the role of SNW1 in prostate cancer are lacking.

Methods

Using immunohistochemistry, we analyzed SNW1 expression in 10,310 prostate cancers in a tissue microarray (TMA) with attached clinical and molecular data.

Results

The comparison with normal prostate tissue revealed an up regulation of SNW1 in a subset of cancer samples. SNW1 staining was considered weak in 31.5%, moderate in 37.7% and strong in 14% of cancers. Strong SNW1 expression was markedly more frequent in prostate cancers harboring the TMPRSS2:ERG fusion (24%) than in ERG negative cancers (7%, p < 0.0001). Significant associations with Gleason grade, stage, nodal status and early biochemical recurrence were observed in the ERG negative and positive subset. Multivariable modeling revealed that the prognostic value of SNW1 up regulation was independent from the established preoperative histopathological and clinical parameters.

Conclusion

These results demonstrate that SNW1 overexpression is an independent prognostic marker in prostate cancer with potential clinical utility.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.PubMed
2.
Leong GM, Subramaniam N, Figueroa J, Flanagan JL, Hayman MJ, Eisman JA, Kouzmenko AP. Ski-interacting protein interacts with Smad proteins to augment transforming growth factor-beta-dependent transcription. J Biol Chem. 2001;276(21):18243–8.CrossRef
3.
Xu W, Angelis K, Danielpour D, Haddad MM, Bischof O, Campisi J, Stavnezer E, Medrano EE. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci U S A. 2000;97(11):5924–9.CrossRef
4.
Prathapam T, Kuhne C, Banks L. Skip interacts with the retinoblastoma tumor suppressor and inhibits its transcriptional repression activity. Nucleic Acids Res. 2002;30(23):5261–8.CrossRef
5.
Wang Y, Fu Y, Gao L, Zhu G, Liang J, Gao C, Huang B, Fenger U, Niehrs C, Chen YG, et al. Xenopus skip modulates Wnt/beta-catenin signaling and functions in neural crest induction. J Biol Chem. 2010;285(14):10890–901.CrossRef
6.
Chen Y, Zhang L, Jones KA. SKIP counteracts p53-mediated apoptosis via selective regulation of p21Cip1 mRNA splicing. Genes Dev. 2011;25(7):701–16.CrossRef
7.
Leong GM, Subramaniam N, Issa LL, Barry JB, Kino T, Driggers PH, Hayman MJ, Eisman JA, Gardiner EM. Ski-interacting protein, a bifunctional nuclear receptor coregulator that interacts with N-CoR/SMRT and p300. Biochem Biophys Res Commun. 2004;315(4):1070–6.CrossRef
8.
Baudino TA, Kraichely DM, Jefcoat SC Jr, Winchester SK, Partridge NC, MacDonald PN. Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem. 1998;273(26):16434–41.CrossRef
9.
Abankwa D, Millard SM, Martel N, Choong CS, Yang M, Butler LM, Buchanan G, Tilley WD, Ueki N, Hayman MJ, et al. Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. BMC Biochem. 2013;14:10.CrossRef
10.
Liu X, Ni Q, Xu J, Sheng C, Wang Q, Chen J, Yang S, Wang H. Expression and prognostic role of SKIP in human breast carcinoma. J Mol Histol. 2014;45(2):169–80.CrossRef
11.
Liu G, Huang X, Cui X, Zhang J, Wei L, Ni R, Lu C. High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. Med Oncol. 2013;30(3):537.CrossRef
12.
Wang L, Zhang M, Wu Y, Cheng C, Huang Y, Shi Z, Huang H. SKIP expression is correlated with clinical prognosis in patients with bladder cancer. Int J Clin Exp Pathol. 2014;7(4):1695–701.PubMedPubMedCentral
13.
Turkcu G, AlabalIk U, Keles AN, Ibiloglu I, Kucukoner M, Sen HS, Buyukbayram H. Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters. Pol J Pathol. 2016;67(2):108–13.CrossRef
14.
Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28(12):1248–50.CrossRef
15.
Erbersdobler A, Fritz H, Schnoger S, Graefen M, Hammerer P, Huland H, Henke RP. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol. 2002;41(1):40–6.CrossRef
16.
Sauter G, Steurer S, Clauditz TS, Krech T, Wittmer C, Lutz F, Lennartz M, Janssen T, Hakimi N, Simon R, et al. Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol. 2016;69(4):592–8.CrossRef
17.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–7.CrossRef
18.
Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013;23(2):159–70.CrossRef
19.
Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res. 2011;17(18):5878–88.CrossRef
20.
Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, et al. Integrative genomic analyses reveal androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 2013;23(2):159–70.CrossRef
21.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.CrossRef
22.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–8.CrossRef
23.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.CrossRef
24.
Brase JC, Johannes M, Mannsperger H, Falth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer. 2011;11:507.CrossRef
25.
Bawa P, Zackaria S, Verma M, Gupta S, Srivatsan R, Chaudhary B, Srinivasan S. Integrative analysis of Normal long intergenic non-coding RNAs in prostate Cancer. PLoS One. 2015;10(5):e0122143.CrossRef
26.
Villar V, Kocic J, Bugarski D, Jovcic G, Santibanez JF. SKIP is required for TGF-beta1-induced epithelial mesenchymal transition and migration in transformed keratinocytes. FEBS Lett. 2010;584(22):4586–92.CrossRef
27.
Burdelski C, Bujupi E, Tsourlakis MC, Hube-Magg C, Kluth M, Melling N, Lebok P, Minner S, Koop C, Graefen M, et al. Loss of SOX9 expression is associated with PSA recurrence in ERG-positive and PTEN deleted prostate cancers. PLoS One. 2015;10(6):e0128525.CrossRef
28.
Burdelski C, Menan D, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Minner S, Koop C, Graefen M, Heinzer H, et al. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer. 2015;15:538.CrossRef
29.
Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Moller-Koop C, Steurer S, Sauter G, et al. High-level gamma-Glutamyl-hydrolase (GGH) expression is linked to poor prognosis in ERG negative prostate Cancer. Int J Mol Sci. 2017;18(2):286. https://​doi.​org/​10.​3390/​ijms18020286.CrossRef
30.
Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki JR, Graefen M, et al. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. Int J Cancer. 2014;135(6):1399–407.CrossRef
31.
Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Comperat E, Evans AJ, Grobholz R, Kristiansen G, Langner C, Lockwood G, et al. Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Arch. 2011;459(2):175–82.CrossRef
Metadata
Title
SNW1 is a prognostic biomarker in prostate cancer
Authors
Doris Höflmayer
Carla Willich
Claudia Hube-Magg
Ronald Simon
Dagmar Lang
Emily Neubauer
Frank Jacobsen
Andrea Hinsch
Andreas M. Luebke
Marie Christina Tsourlakis
Hartwig Huland
Markus Graefen
Alexander Haese
Hans Heinzer
Sarah Minner
Franziska Büscheck
Guido Sauter
Thorsten Schlomm
Stefan Steurer
Till S. Clauditz
Eike Burandt
Waldemar Wilczak
Christian Bernreuther
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2019
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-019-0810-8

Other articles of this Issue 1/2019

Diagnostic Pathology 1/2019 Go to the issue

Case Report

Primordial odontogenic tumor: a case report and literature review

Research

Validation of mitotic cell quantification via microscopy and multiple whole-slide scanners

Correction

Expression of Concern to: Decreased microRNA-224 and its clinical significance in non-small cell lung cancer patients

Case Report

Ipsilateral breast metastasis after axillary dissection caused by epithelioid sarcoma: a case report and pathological investigation

Research

Three-dimensional histopathological reconstruction of bladder tumours

Research

Expression of P63 and its correlation with prognosis in diffuse large B-cell lymphoma: a single center experience